Cancer surveillance in ulcerative colitis and Crohn's disease: New strategies

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Inflammatory bowel disease (IBD) patients have a higher incidence of colon cancer than the general population. Colon cancer surveillance has traditionally involved taking numerous random biopsies to provide sufficient yield to detect dysplasia. Recently, consensus guidelines have been published which promote the use of chromoendoscopy for IBD colon cancer surveillance. This presents a new set of opportunities and challenges in the evaluation and management of dysplasia in IBD. Recent findings Dysplasia, previously thought to be 'invisible' to the endoscopist, is now considered to be 'visible' in the majority of cases with the advent of the use of high-definition endoscopy and chromoendoscopy. This changes how we manage dysplastic lesions, providing the patient options for endoscopic resection rather than promoting total proctocolectomy. Summary Implemention of chromoendoscopy may require additional training for endoscopists unfamiliar with the technique. However, if this proves to be cost-effective and provides a higher sensitivity in dysplasia detection, then widespread education and implementation will be well worth the efforts. To do so, future studies will need to prove its benefits in preventing or reducing colon cancer morbidity and mortality in this high-risk patient population.

Original languageEnglish (US)
Pages (from-to)32-7
Number of pages6
JournalCurrent opinion in gastroenterology
Issue number1
StatePublished - Jan 1 2016


  • Cancer
  • chromoendoscopy
  • Crohn's disease
  • surveillance
  • ulcerative colitis

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Cancer surveillance in ulcerative colitis and Crohn's disease: New strategies'. Together they form a unique fingerprint.

Cite this